Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

News SummaryMost relevantAll newsSector newsTweets

Allergan : Trump to keep Obama rule curbing corporate tax inversion deals

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 04:55pm CEST
U.S. President Donald Trump departs Washington aboard Air Force One

(This October 4 story fixes comment by Organization for International Investment as referring to historically foreign-based companies in paragraph 13.)

President Donald Trump ordered a review almost six months ago of tax rules from the final months of the Obama administration, including ones to discourage companies from redomiciling abroad for tax reasons.

"Treasury plans to retain the distribution requirements under Section 385 pending enactment of tax reform," the department said in a statement, adding "these regulations are necessary to safeguard against earnings stripping."

It also said it planned to revoke and streamline some related documentation rules.

A 2011-2015 wave of inversion deals prompted Treasury to take a series of actions that culminated in an April 2016 rule release and the collapse of a $160-billion deal between U.S. drugmaker Pfizer Inc (>> Pfizer) and Ireland’s Allergan Plc (>> Allergan plc), which would have been the largest inversion ever.

Tax inversions occur when a U.S. company is acquired by a smaller foreign business from a low-tax country and adopts its domicile to reduce the combined firm’s overall U.S. tax burden.

The Section 385 rule was part of Obama's anti-inversion effort and was finalized a year ago. It was meant to combat a corporate tax-reduction technique known as earnings stripping.

Earnings stripping occurs when the U.S. subsidiary of a newly inverted company loads up on debt and avoids taxes on its domestic profits by sending them overseas to the foreign parent in the form of tax-deductible interest payments.

The Obama rule reclassified some forms of debt as equity, changing tax-exempt interest payments into taxable dividends and making earnings stripping strategies more difficult to pursue.

The Organization for International Investment (OFII), a Washington lobbying group for foreign-based companies with U.S. operations, praised the documentation portion of Treasury's latest move and criticized the retention of the rest of the Section 385 rule.

"Unfortunately, in perpetuating an unsubstantiated premise of the Obama administration, Treasury has decided to keep part of these discriminatory regulations," the group said.

Companies with historic foreign headquarters that have expanded into the United States, OFII said in a statement, "are not overleveraged, their debt levels have remained largely flat and their interest expense has declined while their investments into America’s economy have grown."

The Treasury Department said it expected a Republican proposal to overhaul the tax code would eliminate the need for anti-inversion rules. The proposal would sharply cut the corporate tax rate and end taxation of multinationals' foreign profits.

(Writing by Kevin Drawbaugh; Editing by Susan Thomas)

Stocks treated in this article : Allergan plc, Pfizer
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
06:14p Amneal, Impax combine to tackle generic drug pricing pressure
10/16DJALLERGAN : Loses Patent Fight in Federal Court
10/16 ALLERGAN : U.S. District Court for the Eastern District of Texas Issues Adverse ..
10/16 ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
10/16 ALLERGAN : Announces Settlement on RESTASIS 0.05% Patent Litigation with InnoPha..
10/13 ALLERGAN : to Present Data from More Than 20 Abstracts at the 2017 Fall Clinical..
10/12 ALLERGAN : Announces Settlement on RESTASIS® (Cyclosporine Ophthalmic Emulsion) ..
10/12 ALLERGAN : FDA Accepts Supplemental New Drug Application sNDA filing for AVYCAZ®..
10/12 ALLERGAN : To Present New Data From Its Anti-Infectives Portfolio At IDWeek 2017..
10/12 ALLERGAN : Announces that the FDA Accepts New Drug Application for Ulipristal Ac..
More news
News from SeekingAlpha
12:08p Syndax in-licenses blood cancer candidates from Vitae Pharma
10:36a UBS softens outlook on Allergan after adverse Restasis patent ruling; shares ..
09:06a Allergan Punished After Judge Invalidates Restasis Patents
03:50a ALLERGAN : How Bad Is It?
10/16 Allergan Restasis patent-stoked selloff overdone - JPMorgan
Financials ($)
Sales 2017 15 892 M
EBIT 2017 7 624 M
Net income 2017 -3 931 M
Debt 2017 24 536 M
Yield 2017 1,47%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,72x
EV / Sales 2018 5,33x
Capitalization 66 330 M
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 263 $
Spread / Average Target 32%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-2.14%66 330
JOHNSON & JOHNSON18.42%365 346
NOVARTIS13.23%226 956
ROCHE HOLDING LTD.5.20%215 359
PFIZER11.88%214 265